Back to Search
Start Over
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- Source :
- Diabetes Care. 38:2241-2249
- Publication Year :
- 2015
- Publisher :
- American Diabetes Association, 2015.
-
Abstract
- OBJECTIVE This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks. RESEARCH DESIGN AND METHODS In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine. RESULTS The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE HbA1c change from baseline to the primary end point was −1.08 ± 0.06% (−11.8 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, −0.76 ± 0.06% (−8.3 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, and −0.63 ± 0.06% (−6.9 ± 0.7 mmol/mol) for glargine, with an end point mean ± SD dose of 29 ± 26 units (0.33 ± 0.24 units/kg), and a fasting plasma glucose (mean ± SD) of 118 ± 23 mg/dL from self-monitored plasma glucose. Statistical criteria for superiority were met with dulaglutide 1.5 mg and for noninferiority with dulaglutide 0.75 mg. More patients on dulaglutide 1.5 mg achieved HbA1c targets CONCLUSIONS Once-weekly dulaglutide 1.5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia.
- Subjects :
- Blood Glucose
Male
medicine.medical_specialty
Gastrointestinal Diseases
Recombinant Fusion Proteins
Endocrinology, Diabetes and Metabolism
Glucagon-Like Peptides
Urology
Insulin Glargine
Type 2 diabetes
Hypoglycemia
Lower risk
Double-Blind Method
Diabetes mellitus
Internal medicine
Weight Loss
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Aged
Glycated Hemoglobin
Advanced and Specialized Nursing
Insulin glargine
business.industry
Middle Aged
medicine.disease
Metformin
Immunoglobulin Fc Fragments
Glimepiride
Sulfonylurea Compounds
Treatment Outcome
Endocrinology
Diabetes Mellitus, Type 2
Female
Dulaglutide
business
medicine.drug
Subjects
Details
- ISSN :
- 19355548 and 01495992
- Volume :
- 38
- Database :
- OpenAIRE
- Journal :
- Diabetes Care
- Accession number :
- edsair.doi.dedup.....bfc47244d59c99eb33e70c69c16070a4
- Full Text :
- https://doi.org/10.2337/dc14-1625